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ABSTRACT
Chronic inflammation is associated with processes that contribute to the onset or progression of cancer. 
This study examined the correlation between dichotomised patients with malignant tumours and 
inflammatory markers based on the altered glucose metabolism measured by the FDG SUVmax that 
underpins the degree of tumour aggressiveness. Thirty-one patients underwent 18F-FDG PET/CT for 
various carcinoma along with blood inflammatory markers such as C-reactive protein (CRP), interleukin-6 
(IL6), lipid profile and fasting blood glucose (FBG) levels were obtained in retrospective study. Patients 
were dichotomised by the cut-off SUVmax value of 6.0 dl/ml derived from curve analysis (P=-0.025). 
The mean age of the subjects were 53.16 ± 12.06 years and mean SUVmax of 8.80±6.27 g/ml. Significant 
correlation was noted between the SUVmax and CRP and IL6 (r=0.361; P<0.05) and IL-6 with BMI and 
FBG with r=0.38; p<0.05 and r=0.34; p<0.05 respectively.  The odds ratio (95% confidence intervals) for 
patients with the SUVmax cut-off 6.0dl/ml was predicted by FBG ( OR:0.385, p<0.05) and the SUVmax 
> 6.0 dl/ml was inversely related to IL-6 (OR: 0.049, with p<0.005). Serum inflammatory markers and 
endogenous glucose are associated with a potentially more aggressive malignant cancer. In particular, IL6 
may be used as a useful surrogate marker for tumour aggressiveness with an important prognostic value. 
Keywords: Inflammation, Computed tomography, positron emission tomography, [18F]-
fluorodeoxyglucose, multimodality
INTRODUCTION
Development of cancer is significantly 
higher among patients with diabetes. In this 
regard, infection or chronic inflammation 
are associated with mutagenesis in 15-20% 
of all cancers among which are breast, 
colorectal and bronchus followed by cancer 
of liver, stomach and lung (Kuper, 2000; 
Balkwill, 2001; World Cancer Report, 2008). 
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Inflammatory factors, such as interleukin-6 (IL-6), plasminogen activator, inhibitor-1 (PAI-1), 
free fatty acids, monocyte chemo-attractant protein, leptin, fatty acids, adiponectin and tumour 
necrosis factor-α are produced by adipose tissue (Van Kruijsdijk et al., 2009). These factors 
are important in the progression of malignant cancer. In particular, the knowledge of IL-6 for 
immune homeostasis and how it induces profound activities in acute phase reaction has rapidly 
increased in chronic inflammation and carcinogenesis. The progression of cancer resulting 
from chronic inflammation is well known (Naugler et al., 2008). IL-6 is a commander marker 
in promoting inflammation to inflammation-associated cancer (Tangkijvanich et al., 2004). 
In most cases, the level of IL-6 is elevated which favours the development of carcinogenesis. 
In recent decades, multimodality imaging was used to detect early progression of cancer, 
such as MRI, Single-Photon Emission Computed Tomography(SPECT) and Positron Emission 
Tomography PET-CT (Townsend et al., 2008). The PET-CT uses small amount of radiotracer 
to evaluate tissue functions, early onset of disease and lesion localisation via imaging sessions 
(Beyer et al., 2004; Nakamoto et al., 2003; An et al., 2007). The system complements each other 
to detect the lesion and hence help improve diagnostic yield by offering substantial advantages 
over anatomic and physiologic imaging techniques, unlike the standalone PET or CT system. 
The study examined potential association of chronic inflammation and the molecular 
marker – 18 F FDG –PET-CT which contributes to the transformation and early onset of cancer. 
MATERIALS AND METHODS 
Patients
Thirty-one patients with lung carcinoma (11), oesophageal carcinoma (7), metastatic 
paraganglioma (3), colonic carcinoma (3), transitional cell carcinoma (3) and one each with 
lymphoma, hepatoma, nasopharyngeal carcinoma and breast carcinoma were investigated in a 
retrospective study. All patients underwent [18F] fluorodeoxyglucose (FDG)-positron emission 
tomography (PET)/computed tomography (CT) for various indications of disease progression.
Patient Preparation 
All patients fasted for at least 6 hours prior to scanning session and only oral hydration with 
glucose-free water was allowed. Fasting blood glucose was recorded for all patients. Oral 
gastrografin solution (sodium meglumine diatrizoate; BerliMed S.A., Madrid, Spain) was given 
to patients in dilution in three parts before IV administration of radiopharmaceutical agent and 
immediately before scanning. Becquerel range from 290.5 – 415.5 mega (Mean 347.5 MBq) 
of 18F-FDG was injected intravenously. All patients were placed in a special room ranging 
from 23 – 190, for an average of mean 70.6 minutes before they were asked to empty their 
bladder prior to the PET/CT scan imaging study. 
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PET/CT Imaging Protocol
Studies were standardised using a dedicated integrated PET-CT system (Siemens Biograph–64, 
Germany). This device comprises a dedicated PET scanner with Optimum Performance 
in 3-D Imaging with Lutetium Oxyorthosilicate (LSO) scintillator crystal technology. The 
system is incorporated with a multislice CT scanner with capability for 64 slice CT and high 
spatial resolution. For the purpose for attenuation correction, a scout view was performed in 
cranio-caudal direction followed by low dose CT protocol in caudo-cranial. Contrast-enhanced 
CT (CECT) protocol, iohexol (Omnipaque 350 mgI/mL, GE Healthcare, Shanghai, China) 
ranging from 50 – 100 ml with mean 83.07 ml was injected intravenous by using dual head 
automatic pressure injector (Mallinckrodt, M.O, and USA) with flow rate at 2.5 ml per second 
and followed by 20 ml saline flush. At the start of the CT scan, CECT acquisition started in 
caudo-cranial direction with 80 seconds delay, ensuring optimised intravenous (IV) contrast 
in the circulation and tissue enhancement. Subsequently, in view of the higher sensitivity of 
the PET scan, the acquisition time for PET was 2 min per table position. 
 
 
 
Figure	1.	A	circular	region	of	interest	(ROI)	is	drawn	to	evaluate	the	SUVmax	value 
	
Figure 1. A circular region of interest (ROI) is drawn to evaluate the SUVmax value
Image Interpretation
PET/CT scans were read by an experienced radiologist with more than 5 years of clinical 
experience. The radiologist was blinded to the diagnosis and he/she was unaware of any 
biochemical findings or clinical information. The circular region of interest was drawn at the 
FDG-avid area (Figure 1) and the SUVmax value was automatically calculated.
Statistical Analysis
All patients with biopsy-proven cancer were dichotomised into groups based on the cut-off 
SUVmax value of 6.0 derived from the ROC statistical analysis (Figure 2-3). Paired t-test 
(two-tailed) and Wilcoxon signed rank test were used for parameters, which were normally 
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distributed and not normally distributed. Results were evaluated at a 95% confidence interval 
and the level of significance was set as p<0.05. Data was analysed using the Pearson correlation 
coefficient and binary logistic regression. All statistical tests were two-sided, and p values 
<0.05 were considered statistically significant. Data was analysed using Statistical Package 
for Social Sciences program (SPSS 21) (IBM Corp, Somers, New York).
RESULTS AND DISCUSSION
Patient Characteristics
The study investigated 31 retrospective patients (17 males) with mean age of 53.16±12.06 
years. These patients who underwent FDG PET-CT l had biopsy-confirmed lung carcinoma 
(11), oesophageal carcinoma (7), metastatic paraganglioma (3), colonic carcinoma (3), 
transitional cell carcinoma (3) and one each with lymphoma, hepatoma, nasopharyngeal 
carcinoma and breast carcinoma (Table 1). Among them, there were subjects having NIDDM 
(10), Hypertension (16), Hypercholesterolemia (6) & history of smoking (8) with mean BMI 
of 23.56±5.31kg/m2 and FBS 5.30 ± 1.33 g/dl. The mean SUVmax values measured for the 
target lesions was 8.80±6.27 (Table 1).
Table 1 
Patient characteristics  
Patient Age Sex BMI Histology Types FBG CRP IL_6 Cholst Trigl HDL LDL SUVmax
P1 57 F 22 Left lung 
adenoca
Malignant 5.0 122.22 5.39 3.06 1.03 0.49 1.65 7.90
P2 59 F 19 Carcinoma 
esophagus
Malignant 5.0 0.98 6.08 4.27 0.78 1.06 2.56 13.51
P3 33 F 20 Carinoma of 
esophagus
Malignant 5.3 0.63 6.06 4.79 1.31 1.05 3.01 4.08
P4 59 F 21 Adenoca 
esophagus
Malignant 3.5 2.04 6.22 3.81 1.17 1.08 1.79 12.60
P5 50 M 22 Adenoca 
esophagus
Malignant 5.8 0.46 5.94 4.10 0.66 2.07 1.73 5.00
P6 68 F 21 Adenoca 
esophagus
Malignant 3.8 14.59 4.52 5.57 1.52 1.01 3.38 22.64
P7 45 M 29 Melanoma Malignant 5.0 2.22 6.00 6.34 1.10 1.18 4.49 17.66
P8 47 F 23 Adenoca 
esophagus
Malignant 4.3 21.31 5.91 4.04 1.27 0.68 2.60 24.32
P9 56 F 22 Left adrenal 
phaeo
Benign 7.1 0.90 6.12 4.61 2.13 0.93 2.83 4.68
P10 59 F 19 Left lung adeno Malignant 4.3 1.69 6.09 2.74 0.58 0.82 1.76 4.11
P11 60 M 19 Clear cell 
adenoca
Malignant 3.6 2.52 6.18 5.15 1.12 1.88 3.01 6.71
P12 42 F 29 Hepatocellular 
Ca
Malignant 5.3 10.05 5.87 3.50 0.97 0.68 2.63 4.16
P13 64 F 27 Rt chest wall 
tumour
Malignant 6.4 14.94 5.52 2.68 0.94 1.04 1.51 6.15
P14 38 M 33 Lt infraclavicular 
tumour
Malignant 6.7 0.32 6.13 3.86 1.11 0.79 2.85 3.02
P15 70 M 27 Rectal ca with Malignant 6.0 5.65 6.26 3.28 0.97 1.12 2.42 4.50
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Biochemical analysis for inflammatory markers revealed mean CRP of 25.59±53.25U/I, IL-6 
5.87± 0.47U/I with Triglyceride 1.22± 0.52 U/I, HDL.89 ± 0.32 mg/dl and LDL 2.59 ±0.89 
mg/dl (Table 2).
P16 57 F 26 Adrenal tumour Benign 6.6 1.30 6.13 2.55 1.80 0.54 2.07 5.83
P17 61 F 16 Lung cancer Malignant 4.7 184.41 5.36 3.01 0.74 0.62 2.54 10.40
P18 62 M 24 Primary clear 
cell Ca
Malignant 8.0 217.37 6.21 1.26 0.89 0.34 0.57 5.00
P19 63 M 20 Ca pancreas Malignant 5.6 0.73 6.13 3.07 1.06 0.86 2.49 4.40
P20 67 M 22 Ca caecum with Malignant 5.3 13.03 5.77 4.02 1`.48 0.96 3.22 11.40
P21 47 F 20 Adenoca 
esophagus
Malignant 4.4 0.52 6.25 3.15 0.99 0.79 2.57 3.64
P22 59 F 21 Adenoca 
esophagus
Malignant 4.3 1.45 5.26 3.94 1.68 0.86 3.33 3.04
P23 33 M 14 Stage iv NPC Malignant 3.7 11.26 5.82 3.09 1.74 0.67 2.42 9.05
P24 32 F 29 Ca lung Malignant 5.0 2.25 6.05 3.11 2.22 0.85 2.25 2.81
P25 58 M 26 Stage IV ca colon Malignant 5.3 6.90 6.15 3.94 0.63 1.02 3.30 4.70
P26 18 M 23 Adrenal tumour Benign 5.0 186.44 4.78 2.91 0.97 0.56 2.38 20.30
P27 44 M 22 Ca breast Malignant 5.0 15.85 6.17 6.05 0.97 0.90 2.50 13.00
P28 62 M 13 Recurrent gastroc 
Ca
Malignant 2.8 0.51 4.94 3.19 1.91 0.92 2.23 6.12
P29 61 M 34 Recurrent ca 
cecum
Malignant 5.6 17.39 5.88 3.10 1.80 0.55 2.47 20.12
P30 35 F 27 Ca esophagus Malignant 3.8 3.70 6.00 2.95 0.93 0.59 2.37 4.08
P31 61 F 34 Ca lung Malignant 5.0 1.40 5.99 3.47 1.32 0.77 3.01 9.86
Notes: FBG: fasting blood glucose, CRP- C-reactive protein, Cholst: cholesterol, Trigl: triglyceride, 
HDL-high density lipoprotein, LDL: low density lipoprotein, SUVmax: PET-Ct marker (standardised 
uptake values)
Table 1 (continue)
Patient Age Sex BMI Histology Types FBG CRP IL_6 Cholst Trigl HDL LDL SUVmax
Table 2 
Mean biochemical results  
Characteristic Mean ± SD
BMI (kg/m2) 23.56±5.31
FBS (g/dl) 5.30 ± 1.33
CRP (U/l) 25.59±53.25
IL-6 (U/l) 5.87± 0.47
Tg (U/l) 1.22± 0.52
HDL(mg/dl) 0.89 ± 0.32
LDL(mg/dl) 2.59  ±0.89
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Stratification of Patient by the Index of Tumour Aggressiveness (SUVmax) on FDG 
PET
The patients were divided into two groups based on the SUVmax cut-off. Using the Receiver 
operating curve (Figure 2), the cut-off SUVmax of 6.0 was found significant for which (P< 
0.005).
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Figure 2. ROC curve with cut-off value of 6.0.  
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Figure 3. P31: Axial FDG-PET & CT images of a 61 years –old-male ex-smoker with high 
CRP diagnosed with lung carcinoma showing an FDG-avid mass in the right lung (arrowed) 
– SUVmax of 10.40. 
 
 
 
Figure 4. (P17); 18-year-old-male with NIDDM and abdominal paraganglioma (hairline 
marker) (SUVmax: 15.79) 
Figure 3. P31: (a) Axial FDG-PET and (b) CT images of a 61 years –old-male ex-smoker with hig  CRP 
diagnosed with lung carcinoma showing an FDG-avid mass in the right lung (arrowed) – SUVmax of 10.40
(a) (b)
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Correlation Between Inflammatory Markers and SUVmax
Based on spearmen correlation (Table 3), there was strong correlation noted between the CRP 
and SUVmax (P<0.005); r: 0.527). The CRP was also strongly correlated with IL-6 (r=0.361; 
P<0.05). IL-6 was strongly correlated with the BMI (r: 0.38) and FBG (r: 0.34) with (P<0.05) 
respectively.
Table 3 
Spearman Rhos to assess correlation between baseline inflammatory biomarkers and clinical marker and 
the SUVmax   
Interleukin-6 P value
Rho
Age 0.23 0.88
BMI 0.38 *0.01
FBG 0.34 *0.03
CRP  p-value
Rho
SUVmax 0.527 *0.005
IL-6 0.361 *0.05
*statistical significant P<0.05
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Figure 4. (P17); 18-year-old-male with NIDDM and abdominal paraganglioma (hairline 
marker) (SUVmax: 15.79) 
Figure 4. (P17); 18-year-old-male with NIDDM and abdominal paraganglioma (hairline marker) (SUVmax: 
15.79)
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Predictor for the Carcinogenesis (FBS & IL-6)
The Figure 5 shows there is a one-unit increase in the FBS for patients with SUVmax of more 
than 6.0 are 0.38 times the odds of default for patients with SUVmax < 6.0. Conversely a 1-unit 
decrease in IL6 for patients with SUVmax more than 6 is associated with 0.049 times the odd 
of default for patient with lower SUVmax in this category.
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environment. The basis of inflammation in carcinogenesis has been well 
recognised especially in several known cancer i.e. endometrial cancer (Key et 
al.,1988). This study evaluated the imaging marker exploiting glucose analog 
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The primary interest of this study was to evaluate the potential association of the inflammatory 
markers and the altered glucose metabolism in carcinogenic environment. The basis of 
inflammation in carcinogenesis has been well recognised especially in several known cancer 
i.e. endometrial cancer (Key et al.,1988). This study evaluated the imaging marker exploiting 
glucose analog (FDG) as a signal for altered glucose metabolism in different types of cancer 
and potential association with common inflammatory markers. The degr  of altered glucose 
metabolism was measured using the standardised uptake value (SUVmax) of the PET image 
evaluated using PET-CT.
The higher value of SUVmax is correlated with the cellular proliferation and poor prognosis 
(Fathinul et al., 2015). Traditionally, the cut off value for SUVmax 2.5 was used to distinguished 
malignancy from benignity (Fathinul et al., 2015; Fathinul et al., 2014). Given all subjects were 
harbouring malignant cellular entity, the SUVmax of 6.0 was utilised to dichotomise groups 
of cancer patients for which rationale of higher SUVmax value raises the potential of cellular 
stress that underpins the carcinogenic reprogramming. Diabetes mellitus (with fasting blood 
sugar > 7.0 mmol/L) for instance is associated with increased tumour burden (Kaaks et al., 
2002). The study found an association between patient with high glucose level and the altered 
glucose metabolism (SUVmax) which form the basis of strong signalling of the cancer-prone 
environment. The basis of this can be explained by the fact that isoform of the insulin receptor 
expression will induce cancer cells to produce insulin and IGF-I. The A receptor isoform can 
stimulate insulin-mediated mitogenesis and hence, the development of carcinogenic cellularity 
(Denley et al., 2007). There is also a strong correlation between SUVmax and the serum 
C-reactive protein among the cancers subjects. This is in line with other reports which found 
inflammatory process a potential precursor for cancer development (Love et al., 2005). 
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The potential correlation of clinical parameter of patients with evidence of chronic 
inflammation as evidenced by high glycaemic index evaluated by biomarkers i.e. FBS, level 
of total cholesterol and high BMI was investigated. The results showed obesity (high BMI) 
and NIDDM (FBG >7.0 mmol/L) was well correlated with the IL-6. These supported other 
reports which suggested elevated serum level of IL-6 in patient with insulin resistance and 
obesity and correlated with BMI (Kern et al., 2001). This shows cell stress and the alteration 
in cellular reprogramming for the progression of carcinogenesis. 
Lower level of IL-6 in malignant cells of this study was an independent predictor for the 
altered glucose metabolism in malignancy. The basis of low level of IL-6 in association with 
cancer is poorly explained. One of the potential lower IL-6 levels has been described in younger 
age group but will rise with aging (Sarkar et al., 2006). Nevertheless, there was no association 
between low IL-6 with age in this study. In mouse model of colitis-associated cancer (CAC), 
trans-signalling was inhibited by tumour growth factor (TGF-B) to suppress the early onset or 
formation of cancer, which leads to low level of IL-6 in human sample of colon cancer (Atreya 
et al., 2000). The high level of IL-6 explains the carcinogenesis via classical IL-6 signalling. 
This phenomenon is well described in multiple myeloma patients (Lattanzio et al., 1997), which 
show that the high level of IL-6 is associated with vice-versa. Another study found high levels of 
IL-6 expression was correlated with high rates of myeloma protein secretion, low proliferative 
compartment, and low tumour mass. IL-6 induces an undifferentiated tumour cell compartment 
into terminal differentiation (high rate of immunoglobulin production, low proliferative fraction) 
and eventual tumour cell death (low tumour mass (Kishimoto,1989). Therefore, the lower IL-6 
level in an altered glucose metabolism of mitogenesis can be explained by the probable the 
predominant expression of TGF-B which could have suppressed the trans-signalling cancer 
reprogramming pathway in carcinogenesis.
Data was obtained from outpatients and inpatients (a large nationally representative 
sample). The diagnoses were caught blindly and confirmed by the biopsy findings. Limitations 
included a relatively small number of subjects and a lack of other parameters, such as genetics, 
hormones, biochemical, lifestyle and diet. Additionally, the duration for follow-up the onset of 
clinical parameter and biological changes leading to cancer is probably too short.
CONCLUSION
Serum inflammatory markers and endogenous glucose are associated with a potentially more 
aggressive malignant cancer. In particular, IL-6 may be used as a useful surrogate marker for 
tumour aggressiveness with an important prognostic value. The low-level IL-6 indicates the 
cellular reprograming of cancer development has been signalled via different pathway of the 
IL-6 transduction in inflammation-associated cancers and hence, requires further understanding 
of various cancers types on the potential mechanism that regulates the cellular reprogramming. 
The understating of varied levels of IL-6 associated carcinogenesis is important and can be 
used as a marker for treatment efficacy.
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